Follow-up evaluation of cognitive function in the randomized Alzheimer's disease anti-inflammatory prevention trial and its follow-up study

Alzheimer's and Dementia

Volumn 11, Issue 2, 2015, Pages 216-225.e1

  Breitner, John ^a,k   Baker, Laura ^b,j   Drye, Lea ^c   Evans, Denis ^d   Lyketsos, Constantine G ^e   Ryan, Laurie ^f,g   Zandi, Peter ^h   Saucedo, Hector Hernandez ⁱ   Anau, Jane ⁱ   Cholerton, Brenna ⁱ  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g N Bud Grossman Center for Memory Research and Care   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^j SUN HEALTH RESEARCH INSTITUTE   (United States)

^k ROSKAMP INSTITUTE   (United States)

more..

Author keywords

Alzheimer's disease; Celecoxib; Clinical trial; Cognitive function; Naproxen; Nonsteroidal anti inflammatory drug; Prevention

Indexed keywords

CELECOXIB; NAPROXEN; PLACEBO; ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TELEPHONE; DRUG EFFECTS; LONGITUDINAL STUDY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; CELECOXIB; COGNITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; NAPROXEN; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84933675711     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.03.009     Document Type: Article

References (30)

1. Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer's disease. Subcell Biochem 2007;42:229-48.
2. Rozzini R, Ferrucci L, Losonczy K, Havlik RJ, Guralnik JM. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 1996;44:1025-9.
3. Jonker C, Comijs HC, Smit JH. Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol Aging 2003;24:583-8.
4. Gray SL, Hanlon JT, Landerman LR, Artz M, Schmader KE, Fillenbaum GG. Is antioxidant use protective of cognitive function in the community-dwelling elderly? Am J Geriatr Pharmacother 2003;1:3-10.
5. Hayden KM, Zandi PP, Khachaturian AS, Szekely CA, Fotuhi M, Norton MC, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 2007;69:275-82.
6. Bertozzi B, Barbisoni P, Franzoni S, Frisoni GB, Rozzinia R, Trabucchi M. Association of chronic non-steroidal anti-inflammatory drugs use and cognitive decline in non-demented elderly patients admitted to a geriatric evaluation and rehabilitation unit. Arch Gerontol Geriatr 1996;23:71-9.
7. Saag KG, Rubenstein LM, Chrischilles EA, Wallace RB. Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995;22:2142-7.
8. Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008;70:2219-25.
9. May FE, Moore MT, Stewart RB, Hale WE. Lack of association of nonsteroidal anti-inflammatory drug use and cognitive decline in the elderly. Gerontology 1992;38:275-9.
10. Meinert CL, McCaffrey LD, Breitner JC. Alzheimer's Disease Antiinflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement 2009;5:93-104.
11. Breitner JC, Martin BK, Meinert CL. The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen. PLoS Clin Trials 2006;1:e41.
12. Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007; 68:1800-8.
13. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, et al. Cognitive function over time in the Alzheimer's Disease Antiinflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65:896-905.
14. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement epub 2013.
15. ADAPT Steering Committee. Statement from the Steering Committee of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) for communication to the FDA Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee(18 February 2005). 2005.
16. Teng EL, Chui HC. The modified Mini-Mental State (3MS) Examination. Journal of ClinicalPsychiatry 1987;48:314-8.
17. Brandt J. The Hopkins Verbal Learning Test: development of a new verbal memory test with six equivalent forms. The Clinical Neuropsychologist 1991;5:125-42.
18. Clark CM, Ewbank DC. Performance of the Dementia Severity Rating Scale: A caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Disease and AssociatedDisorders 1996;10:31-9.
19. Wechsler D.Wechsler Adult Intelligence Scale-revised manual. New York: Psychological Corporation; 1981.
20. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-65.
21. Wilson BA, Cockburn J, Baddeley A, Hiorns R. The development and validation of a test of everyday memory behavior. J Clin Exp Psychol 1989;11:855-87.
22. BenedictRH, SchrectlenD, Groninger L, DobrashkiM, Shpritz B. Revision of the Brief Visuospatial Memory tests: studies of normal performance, reliability and validity. PsychologicalAssessment 1996;8:153.
23. Squire LR, Wetzel CD, Slater PC. Memory complaint after electroconvulsive therapy: Assessment with a new self-rating instrument. Biol Psychiatry 1979;14:801.
24. Yesavage JA, Brink TL, Rose TL, Leirer VO. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatry Res 1983;17:37-49.
25. Brandt J, Spencer M, FolsteinM. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:111-7.
26. Grodstein F, Skarupski KA, Bienias JL, Wilson RS, Bennett DA, Evans DA. Anti-inflammatory agents and cognitive decline in a biracial population. Neuroepidemiology 2008;30:45-50.
27. Waldstein SR, Wendell CR, Seliger SL, Ferrucci L, Metter EJ, Zonderman AB. Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging. J Am Geriatr Soc 2010;58:38-43.
28. Prince M, Rabe-Hesketh S, Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? An analysis based on data from the MRC treatment trial of hypertension in older adults. Neurology 1998;50:374-9.
29. Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol 2011;68:351-6.
30. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: The epidemiological evidence. CNS Neurol Disord Drug Targets 2010;9:132-9.